{"filing":{"accession_number":"0001193125-26-229714","cik":"0001817241","ticker":null,"company_name":"Artiva Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"artv-20260518.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229714/artv-20260518.htm"},"classifications":[{"id":124,"accession_number":"0001193125-26-229714","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple executive appointments on May 18, 2026: Dr. Miralles as President and Head of R\u0026D (with $600,000 base salary, 45% bonus target, and substantial equity grants of 232,500 options and 77,500 RSUs), and Dr. Aslan as principal financial and accounting officer. While the section also includes departures (Dr. Miralles from the Board, Dr. Aslan from President, and Thad Huston as CFO), the principal disclosed actions center on the appointments of these executives to new roles with defined compensation packages, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:17:21.617090+00:00","company_name":"Artiva Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-05-19"}]}